|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||46.94 - 48.62|
|52-week range||42.10 - 93.94|
|Beta (5Y monthly)||1.86|
|PE ratio (TTM)||103.61|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.50|
Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.
eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to SAR443820/DNL788, a RIPK1 inhibitor, for the treatment of ALS; Sanofi to initiate Phase 2 study in individuals with ALS in Q1 2022Denali to host webinar for analysts and investors today, October 6, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Oct. 06,